CLIN CANCER RES：整合素β3阻滞可以增强ALK抑制剂抗肿瘤活性

2018-09-13 MedSci MedSci原创

ALK阳性肿瘤对小分子ALK酶抑制剂敏感，但是绝大部分患者在治疗期间会出现治疗失败。因此需要新的药物靶点和联合治疗策略。CLIN CANCER RES近期发表了一篇文章，研究ALK表达调节的基因表达以及其在肿瘤进展和治疗方面的意义。

ALK阳性肿瘤对小分子ALK酶抑制剂敏感，但是绝大部分患者在治疗期间会出现治疗失败。因此需要新的药物靶点和联合治疗策略。CLIN CANCER RES近期发表了一篇文章，研究ALK表达调节的基因表达以及其在肿瘤进展和治疗方面的意义。

作者使用免疫组化和荧光监测ALK重排非小细胞肺癌并针对多个基因表达进行分析，并通过临床病理分析验证这些结果。在体外及体内进行细胞系实验，包括抑制和迁移实验等。研究结果表明，ALK重排的非小细胞肺癌患者中，整合素β3过表达基因之一。ALK和整合素β3表达正相关，高整合素β3 mRNA表达与转移和更晚的肿瘤分期有关。此外，作者还发现联合抑制ALK和整合素β3可以在体内及体外增强药物敏感性。

文章最后认为，在ALK重排的非小细胞肺癌中ALK和整合素β3存在正相关关系。高整合素β3表达与肿瘤进展和预后较差有关。这些发现表明整合素β3具有预后价值且对ALK重排非小细胞肺癌患者可以进行ALK和整合素β3联合阻滞治疗。

原始出处：

Ka-Won Noh,Insuk Sohn,et al.Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC.CLIN CANCER RES.September 2018 doi:10.1158/1078-0432.CCR-17-3492

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2019-06-25 mhm289

#肿瘤活性#

70 0
[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2018-11-03 cmj17wellington

#抗肿瘤活性#

109 0
[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2018-12-10 jklm09

#抑制剂#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2018-09-15 12498cf9m36(暂无昵称)

#ALK抑制剂#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2018-09-15 智智灵药

#整合素#

63 0
[GetPortalCommentsPageByObjectIdResponse(id=2034533, encodeId=36a620345333d, content=<a href='/topic/show?id=3a9382989a2' target=_blank style='color:#2F92EE;'>#肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82989, encryptionId=3a9382989a2, topicName=肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Tue Jun 25 20:29:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674955, encodeId=145b16e4955d1, content=<a href='/topic/show?id=5521556518b' target=_blank style='color:#2F92EE;'>#抗肿瘤活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55651, encryptionId=5521556518b, topicName=抗肿瘤活性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf5227147934, createdName=cmj17wellington, createdTime=Sat Nov 03 03:29:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851786, encodeId=84f71851e86fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 10 10:29:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459462, encodeId=fe9e1459462ad, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Sep 15 10:29:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344950, encodeId=396b344950dc, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Sep 14 08:52:44 CST 2018, time=2018-09-14, status=1, ipAttribution=)]
2018-09-14 kafei

学习了谢谢

103 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：整合素β3阻滞可以增强ALK抑制剂抗肿瘤活性

相关资讯

科室

工具

服务